Evaxion Biotech has reported three-year data for EVX-01, its investigational therapeutic melanoma vaccine, according to a company disclosure carried by Investing.com. The headline confirms a three-year follow-up milestone. It does not, in the version available to Derm Field, state the survival figures, the recurrence rate, or the response criteria behind the claim.

That gap matters for dermatologists and oncology-adjacent readers. EVX-01 is a personalized neoantigen vaccine (a vaccine designed from mutations unique to each patient's tumor), a class that has drawn heavy attention since mRNA-4157/V940 showed recurrence-free survival benefit with pembrolizumab in melanoma. A three-year readout in this class would normally be judged on relapse-free survival and overall survival, stratified by AJCC stage (the American Joint Committee on Cancer staging system) at resection. None of those parameters appear in the disclosed headline.

What does the announcement actually contain?

The available disclosure consists of the report itself:

• Company: Evaxion Biotech, a Danish clinical-stage biotech.
• Asset: EVX-01, a therapeutic cancer vaccine candidate for melanoma.
• Milestone: Three-year data reported.

No PASI-style standardized dermatology endpoint applies here; the relevant oncology measures would be relapse-free and overall survival. The announcement as carried does not specify them. Readers should treat the three-year claim as a disclosure event, not an efficacy result, until the full dataset appears.

Why the caveat is necessary

A skeptic's read: three-year durability is the single most persuasive number a neoantigen vaccine program can publish, because most immunotherapy readouts stop at two. If Evaxion held a strong survival curve, the number would likely sit in the first sentence of the release rather than behind the headline. That inference is speculative. It is also the kind of inference investors and clinicians will make regardless, which is precisely why the underlying figures deserve scrutiny when published.

Derm Field could not independently verify cohort size, study design, comparator arm, or statistical significance from the disclosed material. The report as distributed by Investing.com Canada contains no trial registration identifier and no named investigator.

What to watch next

The substantiating detail — cohort, stage distribution, survival endpoints and their confidence intervals — should follow in the full release or a conference presentation. Until then, the three-year mark stands as a timestamp on the program, not as evidence.

For clinicians tracking adjuvant melanoma therapy, the meaningful comparison remains published Phase 2 mRNA-4157 data; EVX-01 will need endpoint-level disclosure before it enters that conversation on evidentiary terms.